TherapeuticsMD (TXMD) FCF Margin (2011 - 2026)

TherapeuticsMD has reported FCF Margin for 16 years, with the latest figure at 130.39% in Q1 2026.

• For the quarter ending Q1 2026, FCF Margin fell 4748.0% year-over-year to 130.39%; the trailing twelve-month figure through Mar 2026 stood at 80.5% (down 3346.0% YoY), and the FY2025 full-year result was 81.2%, up 1476.0% from the prior year.
• FCF Margin for Q1 2026 stood at 130.39%, up from 41.99% in the prior quarter.
• The five-year high for FCF Margin was 5004.52% in Q3 2022, with the low at 11373.58% in Q3 2023.
• Historically, FCF Margin has averaged 1038.33% across 5 years, with a median of 2.55% in 2024.
• Annual changes were most pronounced in 2023 — FCF Margin slumped 1637810 bps — and 2024, when it surged 1136061 bps.
• TherapeuticsMD's FCF Margin stood at 44.1% in 2022, then plunged by 2341 bps to 988.05% in 2023, then jumped by 100 bps to 2.55% in 2024, then soared by 1548 bps to 41.99% in 2025, then surged by 210 bps to 130.39% in 2026.
• The last three FCF Margin figures came in at 130.39% (Q1 2026), 41.99% (Q4 2025), and 127.42% (Q3 2025), per Business Quant data.